RE:RE:RE:2 Trading days left until ER!I agree with you on the specialty pharma names never trading back to teen P/E multiples again but this is not a drug story. Just looking at the larger compares in the sector with hardly any revenue growth of HCA(15x P/E), CYH(15x P/E), UHS(19x P/E). I think a 10 or 11x P/E is just the beginning for NHC, once the Qs starting rolling through the multiple dispersion will compress.